/PRNewswire/ Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin.
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Key eligibility criteria for both trials included adults or adolescents with a diagnosis of AD as defined by the AAD consensus criteria, for at least 1 year prior to screening.
/PRNewswire/ New secondary analysis from Eli Lilly and Company s (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who.